ArticleCancers2022
Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human papillomavirus and prostate cancer in Mexican men: a systematic review and meta-analysis.Cancer causes & control : CCC · 2025Pooled it
- Intense Focal Peripheral Uptake Pattern on 18F-PET/PSMA as a Predictor of Histological Upgrading in Prostate Cancer.The Prostate · 2026Article
- Clinicians' Perspectives on the Impact of Different Attributes of Androgen Receptor Pathway Inhibitors on Prostate Cancer Treatment Preferences and Compliance in Mexico.Oncology and therapy · 2026Article
- Age-Related Epigenetic Drift Shapes Coordinated microRNA Promoter Methylation and Expression in Prostate Cancer.Epigenomes · 2026Article
- Deaths due to malnutrition in children under five in Colombia, 2015-2023: a spatiotemporal analysis.Frontiers in public health · 2026Article
- Global trends in prostate cancer burden among adults aged 80 years and older from 1990 to 2021 based on the global burden of disease 2021.Discover oncology · 2025Article
- Nutrition and Diet in the Prevention and Management of Prostate Cancer in Mexico: A Narrative Review.Nutrients · 2025Review
- Development and Validation of a Predictive Model of Prostate Screening Compliance: A Nationwide Population-Based Study.The Prostate · 2025Observational
- Article
- Global burden of prostate cancer: age-period-cohort analysis from 1990 to 2021 and projections until 2040.World journal of surgical oncology · 2025Article
- Lethal Prostate Cancer in Mexico: Data from the Can.Prost Mexican Registry and a Project for Early Detection.Cancers · 2024Article
- Burden of malignant mesothelioma in China during 1990-2019 and the projections through 2029.Journal of the National Cancer Center · 2024Article
- Article
- Article
- Global Burden of Prostate Cancer and Association with Socioeconomic Status, 1990-2019: A Systematic Analysis from the Global Burden of Disease Study.Journal of epidemiology and global health · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2019, the Global Burden of Disease (GBD) estimated that prostate cancer (PC) was the 16th most common cause of death globally in males. In Mexico, PC epidemiology has been studied by a number of metrics and over various periods, although without including the most up-to-date estimates. Herein, we describe and compare the burdens and trends of PC in Mexico and its 32 states from 2000 to 2019. For this study, we extracted online available data from the GBD 2019 to estimate the crude and age-standardized rates (ASR per 100,000 people) of the incidence and mortality of PC. In Mexico, PC caused 27.1 thousand (95% uncertainty intervals, 20.6-36.0 thousand) incident cases and 9.2 thousand (7.7-12.7 thousand) deaths in males of all ages in 2019. Among the states, Sinaloa had the greatest ASR of incidence, and Guerrero had the highest mortality. The burden of PC showed an increasing trend, although the magnitude of change differed between metrics and locations. We found both an increasing national trend and subnational variation in the burden of PC. Our results confirm the need for updated and timely estimates to design effective diagnostic and treatment campaigns in locations where the burden of PC is the highest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.